Nurix Therapeutics
San Francisco, California, United States · Biopharma, Biotechnology, Health Care
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases. The company is focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cance
Key facts
- Headquarters
- San Francisco, California, United States
- Employees
- 290
- Industries
- Biopharma, Biotechnology, Health Care
- Status
- Public (NRIX)
- Website
- nurixtx.com
- Company page
Recent activity at Nurix Therapeutics
- : Nurix Therapeutics Appoints Wes Burwell as Chief Human Resources Officer
- : SEC 8-K (8.01): On June 11, 2026, the Company announced significant updates from its Phase 1 clinical trial of bexobrutideg (NX-5948), which targets treatment for patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). This update includes safety findings for 142 patients treated at a recommended Phase 2 dose of 600 mg once daily, indicating that the treatment was generally well tolerated with no dose-limiting toxicities. Notably, the updated results reveal an objective response rate of 83% among response-evaluable patients, showcasing promising efficacy even in patients with previously known BTK inhibitor resistance mutations. This disclosure may be crucial for stakeholders monitoring therapeutic advancements in oncology treatments.
- : Nurix Therapeutics Enters License and Collaboration Agreement with Roche
- : Nurix Therapeutics Partners with Roche to Develop Bexobrutideg for B-Cell Malignancies
- : SEC 8-K (1.01): On June 6, 2026, Nurix Therapeutics, Inc. entered into a License and Collaboration Agreement with F. Hoffmann-La Roche Ltd. and Genentech, Inc. Under this agreement, Nurix grants Roche an exclusive worldwide license for its investigational product, bexobrutideg, a small molecule degrader of Bruton’s tyrosine kinase. Roche will make an upfront cash payment of $700 million, with potential total payments up to $2.3 billion. They will co-develop and co-commercialize bexobrutideg in the U.S., while Roche will manage its development outside. The agreement is effective upon clearance under the HSR Act, with shared development costs and profit-sharing terms included.
- : SEC 8-K (1.01): On June 6, 2026, Nurix Therapeutics, Inc. entered into a License and Collaboration Agreement with F. Hoffmann-La Roche Ltd. and Genentech, Inc. This agreement grants Roche an exclusive worldwide license to develop, manufacture, commercialize, and exploit bexobrutideg (NX-5948), a small molecule that targets Bruton’s tyrosine kinase (BTK). The agreement is dated as of June 8, 2026, indicating strategic collaboration in advancing the potential treatment options in oncology. The financial terms and specific conditions of the agreement have not been disclosed, but the collaboration is expected to leverage Nurix's intellectual property rights significantly.
- : SEC 8-K (8.01): On March 6, 2026, Nurix Therapeutics, Inc. entered into Amendment No. 3 to their existing Equity Distribution Agreement with Piper Sandler & Co. This amendment allows the Company to offer and sell up to $413.65 million of shares of common stock through 'at the market' offerings. The amendment builds upon earlier agreements and filings, including an Automatic Shelf Registration Statement. This strategic move enables Nurix to raise capital effectively while leveraging their established relationship with Piper Sandler.
- : SEC 8-K (7.01): On January 12, 2026, Nurix Therapeutics, Inc. presented an overview of its performance for the year 2025 and outlined its key goals for 2026 during the 44th Annual J.P. Morgan Healthcare Conference. This presentation was a significant event for the company, aimed at informing stakeholders and investors about its strategic direction. The presentation materials were attached as Exhibit 99.1, along with a press release issued on the same day, which provided additional insights into the company's objectives and performance metrics. This engagement at a prominent healthcare conference underscores Nurix's commitment to transparency and proactive communication with its investors.
- : SEC 8-K (7.01): On January 12, 2026, Nurix Therapeutics, Inc. presented an overview of its performance in 2025 and outlined its major goals for 2026 at the 44th Annual J.P. Morgan Healthcare Conference. The filing includes the company's presentation materials and a press release, which are attached as Exhibits 99.1 and 99.2. This event is significant as it provides insights into the company's strategic direction and performance metrics, impacting stakeholders' perceptions and potential investments.
- : SEC 8-K (8.01): On December 6, 2025, the Company announced significant clinical data from the Phase 1a/1b trial of bexobrutideg (NX-5948) for patients with relapsed or refractory CLL and SLL. The findings included safety data from all patients, as well as efficacy results showing an 83% objective response rate and a 95.7% disease control rate. Additionally, on December 8, 2025, further clinical data was disclosed for patients with Waldenström macroglobulinemia. The updated Phase 1a results highlighted the treatment's tolerability, a median follow-up of 19 months, and a robust median progression-free survival of 22.1 months, enhancing the significance of the study for future treatments of these hematological malignancies.
Nurix Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Mar 2020 | Venture | $120.2M |
Leadership
- Arthur Sands, Executive Officer, Director
- David Lacey, Director
- Robert Tjian, Director
- Jeff Tong, Director
- Julia Gregory, Director
- Lori Kunkel, Director
- Leon Chen, Director
- Wes Burwell, Chief Human Resources Officer
- Zhengmao Li, Director, Pharmaceutical Development
- Jeffrey Mihalic, Associate Director, Medicinal Chemistry
- Irv Kirschbaum, Hr Consultant, Compensation & Hr Systems
- Simon Vézina-dawod, Scientist Automation and High Throughput Synthesis
Verified email and direct lines for Nurix Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Employee benefit plans
Nurix Therapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Nurix Therapeutics in the news
- Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer - GlobeNewswire (Aug 20, 2026)
- Nurix Initiates DAYBreak Pivotal Study of Bexobrutideg in Relapsed or Refractory Chronic Lymphocytic Leukemia - Investing News Network (Oct 22, 2025)
- Target Acquired, Protein Deleted: The Next Frontier in Precision Medicine and IP Strategy - JD Supra (Apr 28, 2025)
- Nurix Therapeutics Enrolls First Patient in Phase 1b/2 Study of Bexobrutideg Combined with Venetoclax in CLL - Quiver Quantitative (Oct 07, 2026)
- Nurix Therapeutics to Participate in Upcoming September Investor Conferences - Investing News Network (Sep 01, 2026)
- Nurix Therapeutics, Inc. (NRIX) Company Profile & Facts - Yahoo Finance (Oct 09, 2020)
- Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewswire (Jan 06, 2025)
- Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer - Investing News Network (Sep 29, 2026)
Companies similar to Nurix Therapeutics
- Ajax Therapeutics, Inc. · Biopharma, Biotechnology, Health Care, Other, Pharmaceutical, Therapeutics
- MacroGenics · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Tarsus Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Avadel · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
- Crinetics Pharmaceuticals · Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
About Nurix Therapeutics: questions and answers
What does Nurix Therapeutics do?
Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases. The company is focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cance
Where is Nurix Therapeutics headquartered?
Nurix Therapeutics is headquartered in San Francisco, California, United States.
How many employees does Nurix Therapeutics have?
Nurix Therapeutics has about 290 employees.
Has Nurix Therapeutics raised funding?
Yes. Fundz has recorded 1 funding event for Nurix Therapeutics. The most recent, $120.2M, was in Mar 2020.
What is the latest news on Nurix Therapeutics?
On Aug 21, 2026, Nurix Therapeutics Appoints Wes Burwell as Chief Human Resources Officer
Is Nurix Therapeutics a public company?
Yes. Nurix Therapeutics is publicly traded under the ticker NRIX.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy